In The Lancet, Kenneth B Gordon and colleagues1 report the results of the head-to-head UltIMMa-1 and UltIMMa-2 phase 3 trials comparing the efficacy and safety of risankizumab to ustekinumab. Although our repertoire of psoriasis treatments has rapidly advanced in the past 20 years, risankizumab shows particular promise.
Original Article: [Comment] Risankizumab for psoriasis